Nuvalent is a biopharmaceutical company focused on creating targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Co. focuses its discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. In particular, Co. focuses on “clinically proven” kinase targets, or those for which therapies have been developed by others to target those kinases, and that such drugs have demonstrated sufficient clinical efficacy and safety data to be approved by FDA and are established and used in the clinical setting. The NUVL stock yearly return is shown above.
The yearly return on the NUVL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NUVL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|